Regeneron Pharmaceuticals REGN Otarmeni Gene Therapy Launch Shifts LongTerm Narrative Amid Pipeline Execution Focus ARTL Artelo posts far narrower than expected Q4 2025 loss shares edge slightly higher following quarterly earnings release DMRA Damora blows past Q4 2025 EPS estimates but shares fall 264 percent in regular trading